Latest C-peptide Stories
MONTREAL, Nov. 5 /PRNewswire-FirstCall/ -- ConjuChem Biotechnologies Inc. (TSX:CJB) announced today that dosing is complete for its Phase II clinical trial of PC-DAC(TM):Exendin-4.
Bayhill Therapeutics, Inc., a leading developer of therapies for autoimmune diseases, and the Juvenile Diabetes Research Foundation, the world's leading charitable funder of type 1 diabetes research, today announced a partnership to support Bayhill's ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes type 1 diabetes.
CRANBURY, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc.
TEMPE, Ariz., Sept. 3, 2008 (GLOBE NEWSWIRE) -- OrthoLogic Corp. (Nasdaq:OLGC) announced today the publication of positive results from a pre-clinical study of Chrysalin(r) (rusalatide acetate or TP508) in a model of chronic myocardial ischemia.
Tolerx has started a pivotal Phase III clinical trial that is evaluating otelixizumab in autoimmune new onset type 1 diabetes.
JERUSALEM, Israel, August 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP)(http://www.oramed.com/), a developer of oral delivery systems, announced today successful results from the clinical trial of its oral insulin capsule, ORMD 0801.
Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced that it has been issued U.S. Patent number 7,407,940 by the United States Patent and Trademark Office, which includes the company's lead pre-clinical lipohexapeptide candidates.
SAN FRANCISCO, July 30 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. , today announced that Mayo Clinic has initiated a Phase Ib, double-blind, placebo-controlled clinical study of CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure.
-- GelVac(tm) Nasal Powder Platform Delivers Peptide Arginine-Vasopressin (AVP) Into Systemic Circulation -- Peptide Widely Used to Control Urine Output in Patients With Diabetes Insipidus -- Additional Commercial Opportunities Could Include a Treatment for Heart Failure -- Formulation Stable at Room Temperature For More Than 18 Months IRVING, Texas, July 15, 2008 (PRIME NEWSWIRE) -- DelSite, Inc.
SAN FRANCISCO, July 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc.
- Sleep; the state or condition of being asleep.
- The state or condition of numbness of a part due to pressure on a nerve: as, the obdormition of a limb.